
Opinion|Videos|March 6, 2025
Comparing Approved ADC Options in HER2-Negative and HER2-Low Breast Cancer
Panelists discuss how antibody-drug conjugates (ADCs) for breast cancer (BC) differ in their safety profiles, with trastuzumab deruxtecan (T-DXd) having notable interstitial lung disease risk, sacituzumab govitecan (SG) associated with neutropenia/diarrhea, and datopotamab deruxtecan (Dato-DXd) showing a relatively favorable safety profile but still requiring monitoring.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- Could you walk through the ADC therapies that are approved for HR+ HER2-negative/low and triple-negative BC?
- What key differences in the safety of T-DXd, SG, and Dato-DXd are important for pharmacists to understand?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
2
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
3
Afamitresgene autoleucel: The First T-Cell Receptor Therapy on the Market
4
FDA Approves Depemokimab as Add-On Maintenance Treatment in Severe Asthma
5











































































































































































































